University of Texas's MD Anderson Cancer: Belzutifan Induced Strong Responses in Patients With Von Hippel-Lindau Disease-Associated Kidney Cancer
November 25, 2021
November 25, 2021
HOUSTON, Texas, Nov. 25 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Nov. 24, 2021:
* * *
MD Anderson-led Phase II study resulted in first FDA-approved therapy for VHL disease
* * *
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, . . .
* * *
MD Anderson-led Phase II study resulted in first FDA-approved therapy for VHL disease
* * *
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, . . .